Join to view full profile
3332 Old Montgomery HwySte 103Homewood, AL 35209
Phone+1 205-930-0920
Fax+1 205-445-0115
Dr. Navari is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Rudolph Navari is an oncologist in Birmingham, AL and is affiliated with multiple hospitals in the area, including St. Vincent Kokomo, Saint Joseph Health System, University of Alabama Hospital, and University of Alabama Hospital. He received his medical degree from Virginia Commonwealth University School of Medicine and has been in practice 40 years. He specializes in hematologic oncology.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 1981 - 1983
University of Alabama Hospital (Birmingham)Residency, Internal Medicine, 1977 - 1980
Virginia Commonwealth University School of MedicineClass of 1977
Certifications & Licensure
FL State Medical License 2023 - Present
MS State Medical License 2016 - 2027
OR State Medical License 2023 - 2027
AL State Medical License 1978 - 2026
IN State Medical License 1998 - 2025
MO State Medical License 2020 - 2025
IL State Medical License 1998 - 1999
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy Start of enrollment: 2014 Aug 20
- Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients Start of enrollment: 2017 Jul 12
- Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy Start of enrollment: 2018 Nov 20
Publications & Presentations
PubMed
- Individual patient data meta-analysis of NEPA versus aprepitant-based antiemetic regimens for preventing chemotherapy-induced nausea and vomiting.Rudolph M Navari, Timothy Tyler, Naoki Inui, Hirotoshi Iihara, Erminio Bonizzoni
Future Oncology. 2025-09-01 - 3 citationsNEPA (Netupitant/Palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Highly or Moderately Emetogenic Chemotherapy...Rudolph M Navari, Erminio Bonizzoni
Cancer Medicine. 2025-04-01 - 9 citationsNausea and vomiting in an evolving anticancer treatment landscape: long-delayed and emetogenic antibody-drug conjugates.Yeon Hee Park, Giampaolo Bianchini, Javier Cortés, Luca Licata, María Vidal
Future Oncology. 2025-04-01
Journal Articles
- The Importance of a Cause-Based Protocol to Approach Cancer-Related Nausea and Vomiting—ReplyCharles L Loprinzi, Rudolph M Navari, JAMA Oncology
- Olanzapine for the Treatment of Advanced Cancer–Related Chronic Nausea and/or VomitingRudolph M Navari, Costantine Albany, Charles L Loprinzi, JAMA Oncology
Authored Content
- Olanzapine for the Treatment of Advanced Cancer–Related Chronic Nausea and/or VomitingMay 2020
- Olanzapine for the Treatment of Advanced Cancer–Related Chronic Nausea and/or VomitingMay 2020
Press Mentions
Helsinn Publishes Results from a Secondary Analysis of a Phase 3 Trial in Patients with CINV Helsinn Publishes Results from a Secondary Analysis of a Phase 3 Trial in Patients with CINVJanuary 4th, 2023
FDA Updates Highlighting the Latest Cancer TreatmentsNovember 20th, 2019
Study Finds Guideline Adoption Slow for Antiemetic Prophylaxis in Patients Receiving CarboplatinNovember 2nd, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
